CSL Behring LLC

Haemophilia B and Gene Therapy

Research activity includes haemophilia B and Hemophilia B, with a strong emphasis on AAV-based gene therapy, factor IX expression, and long-term control of bleeding risk in adolescent and adult populations.

  • Factor IX replacement
  • Bleeding prevention
  • AAV vector therapy
  • Long-term safety follow-up

Clinical interest also extends to neutralizing antibodies and sustained treatment outcomes after gene-based intervention.

Hereditary Angioedema

The sponsor funds studies in hereditary angioedema, Hereditary Angioedema (HAE), and Hereditary angioedema (HAE), focusing on prophylaxis, attack prevention, and treatment switching across adult and pediatric groups.

  • C1-inhibitor deficiency
  • Angioedema prophylaxis
  • Attack prevention
  • Pediatric HAE care

Research includes both subcutaneous and intravenous approaches for controlling recurrent swelling episodes.

Sickle Cell Disease and Vaso-occlusive Crisis

Trials in sickle cell disease, Sickle Cell Disease, and sickle cell disease vaso-occlusive crisis examine symptom relief, crisis resolution, and safety in affected adults and adolescents.

  • Vaso-occlusive crisis
  • Hemolytic complications
  • Acute symptom management
  • Supportive biologic therapy

Additional work addresses anemia-related complications and disease burden during acute episodes.

Immune-Mediated and Inflammatory Disorders

The portfolio includes acute graft-versus-host disease, dermatomyositis, and related immune-mediated inflammatory disorders, reflecting interest in transplant-associated and systemic autoimmune conditions.

  • Graft-versus-host disease
  • Dermatomyositis
  • Hematopoietic cell transplant
  • Immune modulation

These studies focus on disease control in settings where immune dysregulation drives tissue injury and persistent symptoms.

Renal, Pulmonary, and Metabolic Conditions

Research also covers atherosclerotic cardiovascular disease in patients with ESKD, non-cystic fibrosis bronchiectasis, homeostatic iron regulator gene-related hereditary hemochromatosis, and post-COVID-19 postural orthostatic tachycardia syndrome.

  • End-stage kidney disease
  • Bronchiectasis
  • Hereditary hemochromatosis
  • Post-COVID dysautonomia

These areas include interest in cardiovascular inflammation, iron overload, and chronic respiratory or autonomic complications.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Safety Study of Switching from Current Treatment to Garadacimab in Patients Age 12 and Older with Hereditary Angioedema

    Not recruiting

    3 1 1
    Investigated Drugs:
    Germany
  • Study on the Effectiveness of Human Normal Immunoglobulin for Adults with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

    Not recruiting

    3 1 1
    Germany Italy Spain
  • Study on the Safety and Effectiveness of CSL889 for Adults and Adolescents with Sickle Cell Disease During Painful Crises

    Not recruiting

    4 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Greece Italy The Netherlands +1
  • Title: Study of gene therapy Etranacogene Dezaparvovec (Hemgenix) in adult patients with moderate to severe Hemophilia B

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark Germany Ireland The Netherlands Sweden
  • Long-term Safety Study of Etranacogene Dezaparvovec in Adult Men with Hemophilia B

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Denmark Germany Ireland The Netherlands Sweden
  • Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Hungary Italy Poland +1